RenovoRx, Inc. — Form 8-K
Filed November 20, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
RenovoRx appointed Richard A. Stark, CEO of Innoblative Designs and founder of RAS Consulting Firm, to its Board of Directors on November 19, 2026. Stark has advised RenovoRx since late 2024 on commercialization strategy for its RenovoCath device and TAMP platform in interventional oncology. No equity or compensation details were disclosed in this filing.
Why this rating
Board appointment is routine governance; Stark's advisory role already embedded. No material financial impact disclosed. Standard for early-stage biotech. Neutral signal on execution capability.
See more from November 20, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.